Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia

Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia Single-arm design with a 24-week run-in followed by 48 weeks of treatment; primary endpoint is annualized treated bleed rate CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sus